Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vobramitamab duocarmazine · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Cohort -1 | EXPERIMENTAL | vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks |
| Cohort 1 | EXPERIMENTAL | vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks |
| Cohort 2 | EXPERIMENTAL | vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks |
| Cohort 3 | EXPERIMENTAL | vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks |
| Cohort 4 | EXPERIMENTAL | vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks |
| Cohort 5 | EXPERIMENTAL | vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks |
| Cohort Expansion | EXPERIMENTAL | maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks |
| Name | Type | Description |
|---|---|---|
| vobramitamab duocarmazine | BIOLOGICAL | Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3. |
| lorigerlimab | BIOLOGICAL | Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4. |
Inclusion Criteria: * 1\. Ability to provide and document informed consent and willing and able to comply with all study procedures. * Participants diagnosed with advanced solid tumors including but not limited to metastatic castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatoc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Vobramitamab duocarmazine is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors, including castration-resistant prostate cancer, malignant melanoma, pancreatic ductal carcinoma, hepatocellular cancer, epithelial ovarian cancer, and renal cell carcinoma. It is currently in Phase 1 clinical development.
Vobramitamab duocarmazine is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol MGNX. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
Vobramitamab duocarmazine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial that enrolled 31 participants with advanced solid tumors.
Vobramitamab duocarmazine was studied in clinical trial NCT05293496, titled 'A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors.' This Phase 1 trial was completed and enrolled 31 participants in the United States, with a minimum age of 18 years.
Yes, vobramitamab duocarmazine is also known as MGC018. The clinical trial NCT05293496 refers to the drug as MGC018, and it is being studied in combination with MGD019 for the treatment of advanced solid tumors.